Pharmafile Logo
Pharmafocus logo
Advanced Search

BRAF protein

Showing 3 posts of 3 posts found.

Daiichi Sankyo gains rights to potential blockbuster cancer drug

March 2, 2011
Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine

Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …

News
Roche Severin Schwann

Roche weathers tough year and looks to pipeline for 2011

February 3, 2011
Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab

Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …

News

Roche’s melanoma candidate impresses in phase II trials

November 5, 2010
Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche

Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026